Your browser doesn't support javascript.
loading
The Role of Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease.
Kalaoja, Marita; Corbin, Laura J; Tan, Vanessa Y; Ahola-Olli, Ari V; Havulinna, Aki S; Santalahti, Kristiina; Pitkänen, Niina; Lehtimäki, Terho; Lyytikäinen, Leo-Pekka; Raitoharju, Emma; Seppälä, Ilkka; Kähönen, Mika; Ripatti, Samuli; Palotie, Aarno; Perola, Markus; Viikari, Jorma S; Jalkanen, Sirpa; Maksimow, Mikael; Salomaa, Veikko; Salmi, Marko; Raitakari, Olli T; Kettunen, Johannes; Timpson, Nicholas J.
Afiliação
  • Kalaoja M; Computational Medicine, Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
  • Corbin LJ; Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Tan VY; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • Ahola-Olli AV; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Havulinna AS; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • Santalahti K; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Pitkänen N; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Lehtimäki T; Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lyytikäinen LP; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland.
  • Raitoharju E; Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Seppälä I; Medicity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.
  • Kähönen M; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
  • Ripatti S; Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
  • Palotie A; Department of Clinical Chemistry, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Perola M; Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
  • Viikari JS; Department of Clinical Chemistry, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Jalkanen S; Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
  • Maksimow M; Department of Clinical Chemistry, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Salomaa V; Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
  • Salmi M; Department of Clinical Chemistry, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Raitakari OT; Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.
  • Kettunen J; Department of Clinical Physiology, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Timpson NJ; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland.
Obesity (Silver Spring) ; 29(2): 428-437, 2021 02.
Article em En | MEDLINE | ID: mdl-33491305
ABSTRACT

OBJECTIVE:

This study aimed to investigate the role of cytokines as intermediates in the pathway from increased adiposity to disease.

METHODS:

BMI and circulating levels of up to 41 cytokines were measured in individuals from three Finnish cohort studies (n = 8,293). Mendelian randomization (MR) was used to assess the impact of BMI on circulating cytokines and the impact of BMI-driven cytokines on risk of obesity-related diseases.

RESULTS:

Observationally, BMI was associated with 19 cytokines. For every SD increase in BMI, causal effect estimates were strongest for hepatocyte growth factor, monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and were as ratios of geometric means 1.13 (95% CI 1.08-1.19), 1.08 (95% CI 1.04-1.14), and 1.13 (95% CI 1.04-1.21), respectively. TRAIL was associated with a small increase in the odds of coronary artery disease (odds ratio 1.03; 95% CI 1.00-1.06). There was inconsistent evidence for a protective role of MCP-1 against inflammatory bowel diseases.

CONCLUSIONS:

Observational and MR estimates of the effect of BMI on cytokine levels were generally concordant. There was little evidence for an effect of raised levels of BMI-driven cytokines on disease. These findings illustrate the challenges of MR when applied in the context of molecular mediation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citocinas / Adiposidade / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Obesity (Silver Spring) Assunto da revista: CIENCIAS DA NUTRICAO / FISIOLOGIA / METABOLISMO Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Finlândia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citocinas / Adiposidade / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Obesity (Silver Spring) Assunto da revista: CIENCIAS DA NUTRICAO / FISIOLOGIA / METABOLISMO Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Finlândia